<p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “卖出” 评级上调至 “持有” 评级。</p>
<p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
<p>其他一些研究分析师最近也对 TSHA 发布了报告。Raymond James Financial 于 10 月 21 日星期二开始对 Taysha Gene Therapies 的股票进行覆盖。他们对该股票设定了 “强力买入” 评级和 13.00 美元的目标价。JMP Securities 在 11 月 5 日星期三的研究报告中对 Taysha Gene Therapies 的股票设定了 8.00 美元的目标价。Weiss Ratings 在周一的研究报告中重新发布了 Taysha Gene Therapies 的 “卖出（d-）” 评级。花旗集团在 11 月 5 日星期三的研究报告中重申了 Taysha Gene Therapies 的 “跑赢大盘” 评级。最后，Robert W. Baird 在 10 月 2 日星期四的研究报告中将 Taysha Gene Therapies 的目标价从 7.00 美元上调至 12.00 美元，并给予该股票 “跑赢大盘” 评级。一位分析师给予该股票 “强力买入” 评级，十一位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 10.42 美元。</p>
<p><strong>查看我们关于 TSHA 的最新研究报告</strong></p>
<h2>Taysha Gene Therapies 股票上涨 0.5%</h2>
<ul>
<li>3 只小盘股适合你的秋季购物清单</li>
</ul>
<p>Taysha Gene Therapies 的股票在周五开盘价为 5.79 美元。该股票的 50 日移动平均线为 4.69 美元，200 日移动平均线为 3.47 美元。Taysha Gene Therapies 的一年低点为 1.05 美元，一年高点为 5.95 美元。该公司的市值为 15.9 亿美元，市盈率为-17.55，贝塔系数为 1.06。该公司的债务与股本比率为 0.23，流动比率为 10.48，速动比率为 10.48。</p>
<p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）最近在 11 月 4 日星期二发布了季度财报。公司报告每股收益（EPS）为（0.09 美元），符合市场共识预期（0.09 美元）。Taysha Gene Therapies 的股本回报率为-67.26%，净利润率为-1,144.97%。股票研究分析师预计 Taysha Gene Therapies 在本年度将发布-0.35 的每股收益。</p>
<h2>Taysha Gene Therapies 的内部买卖情况</h2>
<p>在相关消息中，内部人士 Sukumar Nagendran 于 12 月 1 日星期一出售了 260,047 股公司的股票。股票以平均价格 4.51 美元出售，总价值为 1,172,811.97 美元。交易后，内部人士持有公司 1,006,439 股股票，价值约为 4,539,039.89 美元。此次交易代表其持股比例下降了 20.53%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。3.78% 的股票由公司内部人士持有。</p>
<h2>Taysha Gene Therapies 的机构交易情况</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对 TSHA 的持股。先锋集团在第三季度将其在 Taysha Gene Therapies 的持股增加了 17.9%。先锋集团目前拥有 12,849,613 股公司股票，价值 42,018,000 美元，此前在上个季度又购买了 1,955,486 股。Octagon Capital Advisors LP 在第二季度将其在 Taysha Gene Therapies 的持股增加了 17.7%。Octagon Capital Advisors LP 目前拥有 12,592,500 股公司股票，价值 29,089,000 美元，此前在上个季度又购买了 1,892,500 股。Jefferies Financial Group Inc. 在第二季度将其在 Taysha Gene Therapies 的持股增加了 4,105.3%。Jefferies Financial Group Inc. 目前拥有 10,313,733 股公司股票，价值 23,825,000 美元，此前在上个季度又购买了 10,068,479 股。Vestal Point Capital LP 在第三季度将其在 Taysha Gene Therapies 的持股增加了 83.3%。Vestal Point Capital LP 目前拥有 5,500,000 股公司股票，价值 17,985,000 美元，此前在上个季度又收购了 2,500,000 股。最后，Polar Capital Holdings Plc 在第三季度将其在 Taysha Gene Therapies 的持股增加了 5.9%。Polar Capital Holdings Plc 目前拥有 5,293,879 股公司股票，价值 17,311,000 美元，此前在上个季度又收购了 293,879 股。77.70% 的股票由机构投资者持有。</p>
<h2>Taysha Gene Therapies 公司简介</h2>
<p>（获取免费报告）</p>
<p>Taysha Gene Therapies, Inc. 是一家基因治疗公司，专注于开发和商业化基于腺病毒相关病毒的基因治疗，用于治疗中枢神经系统的单基因疾病。它主要开发 TSHA-120 用于治疗巨轴神经病；TSHA-102 用于治疗 Rett 综合症；TSHA-121 用于治疗 CLN7 疾病；TSHA-118 用于治疗 CLN1 疾病；TSHA-105 用于治疗 SLC13A5 缺乏症；TSHA-113 用于治疗 tauopathies；TSHA-106 用于治疗 Angelman 综合症；TSHA-114 用于治疗脆性 X 综合症；以及 TSHA-101 用于治疗 GM2 神经节苷脂症。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Taysha Gene Therapies</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>Synopsys 看到乐观转变，因 Ansys 整合推动增长</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>为什么 Zscaler 股票在经历 30% 抛售后可能准备反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Taysha Gene Therapies 吗？</h2>
<p>在考虑 Taysha Gene Therapies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Taysha Gene Therapies 并不在名单上。</p>
<p>虽然 Taysha Gene Therapies 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TSHA

<p>华尔街禅将 Taysha Gene Therapies（纳斯达克代码：TSHA）的评级从 “卖出” 上调至 “持有”。其他分析师的评级各不相同，有的给予 “强烈买入” 和 “跑赢大盘” 的评级。该股票开盘价为 5.79 美元，市值为 15.9 亿美元。包括先锋集团和杰富瑞在内的机构投资者已增加了对该公司的持股。内部交易活动有所增加，内部人士进行了大额出售。该公司专注于单基因疾病的基因疗法</p>

<p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的投资分析师从 “卖出” 评级上调至 “持有” 评级。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on TSHA. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a research report on Tuesday, October 21st. They set a &#34;strong-buy&#34; rating and a $13.00 target price on the stock. JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Monday. Citigroup restated an &#34;outperform&#34; rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Robert W. Baird upped their price target on Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $10.42.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对 TSHA 发布了报告。Raymond James Financial 于 10 月 21 日星期二开始对 Taysha Gene Therapies 的股票进行覆盖。他们对该股票设定了 “强力买入” 评级和 13.00 美元的目标价。JMP Securities 在 11 月 5 日星期三的研究报告中对 Taysha Gene Therapies 的股票设定了 8.00 美元的目标价。Weiss Ratings 在周一的研究报告中重新发布了 Taysha Gene Therapies 的 “卖出（d-）” 评级。花旗集团在 11 月 5 日星期三的研究报告中重申了 Taysha Gene Therapies 的 “跑赢大盘” 评级。最后，Robert W. Baird 在 10 月 2 日星期四的研究报告中将 Taysha Gene Therapies 的目标价从 7.00 美元上调至 12.00 美元，并给予该股票 “跑赢大盘” 评级。一位分析师给予该股票 “强力买入” 评级，十一位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，平均目标价为 10.42 美元。</p>
</div><p><strong>View Our Latest Research Report on TSHA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TSHA 的最新研究报告</strong></p>
</div><h2>Taysha Gene Therapies Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股票上涨 0.5%</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股适合你的秋季购物清单</li>
</ul>
</div><p>Shares of Taysha Gene Therapies stock opened at $5.79 on Friday. The stock's 50-day moving average is $4.69 and its 200 day moving average is $3.47. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $5.95. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -17.55 and a beta of 1.06. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 的股票在周五开盘价为 5.79 美元。该股票的 50 日移动平均线为 4.69 美元，200 日移动平均线为 3.47 美元。Taysha Gene Therapies 的一年低点为 1.05 美元，一年高点为 5.95 美元。该公司的市值为 15.9 亿美元，市盈率为-17.55，贝塔系数为 1.06。该公司的债务与股本比率为 0.23，流动比率为 10.48，速动比率为 10.48。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）最近在 11 月 4 日星期二发布了季度财报。公司报告每股收益（EPS）为（0.09 美元），符合市场共识预期（0.09 美元）。Taysha Gene Therapies 的股本回报率为-67.26%，净利润率为-1,144.97%。股票研究分析师预计 Taysha Gene Therapies 在本年度将发布-0.35 的每股收益。</p>
</div><h2>Insider Buying and Selling at Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的内部买卖情况</h2>
</div><p>In related news, insider Sukumar Nagendran sold 260,047 shares of the firm's stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares of the company's stock, valued at approximately $4,539,039.89. This trade represents a 20.53% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 3.78% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Sukumar Nagendran 于 12 月 1 日星期一出售了 260,047 股公司的股票。股票以平均价格 4.51 美元出售，总价值为 1,172,811.97 美元。交易后，内部人士持有公司 1,006,439 股股票，价值约为 4,539,039.89 美元。此次交易代表其持股比例下降了 20.53%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。3.78% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的机构交易情况</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Vanguard Group Inc. lifted its holdings in shares of Taysha Gene Therapies by 17.9% in the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company's stock valued at $42,018,000 after purchasing an additional 1,955,486 shares in the last quarter. Octagon Capital Advisors LP grew its holdings in Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company's stock worth $29,089,000 after buying an additional 1,892,500 shares in the last quarter. Jefferies Financial Group Inc. raised its position in Taysha Gene Therapies by 4,105.3% in the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company's stock valued at $23,825,000 after buying an additional 10,068,479 shares during the last quarter. Vestal Point Capital LP lifted its stake in Taysha Gene Therapies by 83.3% during the 3rd quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company's stock valued at $17,985,000 after acquiring an additional 2,500,000 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its holdings in Taysha Gene Therapies by 5.9% during the 3rd quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company's stock worth $17,311,000 after acquiring an additional 293,879 shares during the last quarter. 77.70% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对 TSHA 的持股。先锋集团在第三季度将其在 Taysha Gene Therapies 的持股增加了 17.9%。先锋集团目前拥有 12,849,613 股公司股票，价值 42,018,000 美元，此前在上个季度又购买了 1,955,486 股。Octagon Capital Advisors LP 在第二季度将其在 Taysha Gene Therapies 的持股增加了 17.7%。Octagon Capital Advisors LP 目前拥有 12,592,500 股公司股票，价值 29,089,000 美元，此前在上个季度又购买了 1,892,500 股。Jefferies Financial Group Inc. 在第二季度将其在 Taysha Gene Therapies 的持股增加了 4,105.3%。Jefferies Financial Group Inc. 目前拥有 10,313,733 股公司股票，价值 23,825,000 美元，此前在上个季度又购买了 10,068,479 股。Vestal Point Capital LP 在第三季度将其在 Taysha Gene Therapies 的持股增加了 83.3%。Vestal Point Capital LP 目前拥有 5,500,000 股公司股票，价值 17,985,000 美元，此前在上个季度又收购了 2,500,000 股。最后，Polar Capital Holdings Plc 在第三季度将其在 Taysha Gene Therapies 的持股增加了 5.9%。Polar Capital Holdings Plc 目前拥有 5,293,879 股公司股票，价值 17,311,000 美元，此前在上个季度又收购了 293,879 股。77.70% 的股票由机构投资者持有。</p>
</div><h2>Taysha Gene Therapies Company Profile</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc. 是一家基因治疗公司，专注于开发和商业化基于腺病毒相关病毒的基因治疗，用于治疗中枢神经系统的单基因疾病。它主要开发 TSHA-120 用于治疗巨轴神经病；TSHA-102 用于治疗 Rett 综合症；TSHA-121 用于治疗 CLN7 疾病；TSHA-118 用于治疗 CLN1 疾病；TSHA-105 用于治疗 SLC13A5 缺乏症；TSHA-113 用于治疗 tauopathies；TSHA-106 用于治疗 Angelman 综合症；TSHA-114 用于治疗脆性 X 综合症；以及 TSHA-101 用于治疗 GM2 神经节苷脂症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>Synopsys Sees Bullish Shift as Ansys Integration Drives Growth</li>
<li>How to Most Effectively Use the MarketBeat Earnings Screener</li>
<li>The Best Holiday Present You Can Give Yourself? Costco Stock</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Taysha Gene Therapies</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>Synopsys 看到乐观转变，因 Ansys 整合推动增长</li>
<li>如何最有效地使用 MarketBeat 财报筛选器</li>
<li>你能给自己最好的节日礼物是什么？Costco 股票</li>
<li>现在购买的三只最佳金融科技股票</li>
<li>为什么 Zscaler 股票在经历 30% 抛售后可能准备反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Taysha Gene Therapies 吗？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Taysha Gene Therapies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Taysha Gene Therapies 并不在名单上。</p>
</div><p>While Taysha Gene Therapies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Taysha Gene Therapies 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Taysha Gene Therapies（纳斯达克股票代码：TSHA）的评级在 Wall Street Zen 被上调至持有